Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High treatment adherence, satisfaction, motivation, and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis - results from a 24-month, multicenter, open-label Danish study.
Schreiber K, Kant M, Pfleger C, Jensen HB, Oesterberg O, Hald AR, Nielsen FK, Rubak S. Schreiber K, et al. Among authors: kant m. Patient Prefer Adherence. 2018 Jun 29;12:1139-1150. doi: 10.2147/PPA.S166278. eCollection 2018. Patient Prefer Adherence. 2018. PMID: 29988735 Free PMC article.
Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark.
Papp V, Illes Z, Magyari M, Koch-Henriksen N, Kant M, Pfleger CC, Roemer SF, Jensen MB, Petersen AE, Nielsen HH, Rosendahl L, Mezei Z, Christensen T, Svendsen K, Hyldgaard Jensen PE, Lydolph MC, Heegaard N, Frederiksen JL, Sellebjerg F, Stenager E, Petersen T. Papp V, et al. Among authors: kant m. Neurology. 2018 Dec 11;91(24):e2265-e2275. doi: 10.1212/WNL.0000000000006645. Epub 2018 Nov 9. Neurology. 2018. PMID: 30413632 Free PMC article.
Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
Buron MD, Chalmer TA, Sellebjerg F, Barzinji I, Danny B, Christensen JR, Christensen MK, Hansen V, Illes Z, Jensen HB, Kant M, Papp V, Petersen T, Prakash S, Rasmussen PV, Schäfer J, Theódórsdóttir Á, Weglewski A, Sorensen PS, Magyari M. Buron MD, et al. Among authors: kant m. Neurology. 2020 Aug 25;95(8):e1041-e1051. doi: 10.1212/WNL.0000000000010135. Epub 2020 Jul 7. Neurology. 2020. PMID: 32636328
Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES).
Riemenschneider M, Hvid LG, Ringgaard S, Nygaard MKE, Eskildsen SF, Gaemelke T, Magyari M, Jensen HB, Nielsen HH, Kant M, Falah M, Petersen T, Stenager E, Dalgas U. Riemenschneider M, et al. Among authors: kant m. Mult Scler. 2022 Sep;28(10):1620-1629. doi: 10.1177/13524585221079200. Epub 2022 Mar 16. Mult Scler. 2022. PMID: 35296183 Clinical Trial.
Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study.
Roar M, Nielsen ARH, Berg JM, Sirakov G, Stilund M, Schäfer J, Ratzer R, Frederiksen J, Asgari N, Ashna SN, Jensen HB, Kant M, Theódorsdóttir Á, Illes Z, Sellebjerg F, Magyari M, Schlosser LM, Nordborg H, Wergeland S, Sejbaek T. Roar M, et al. Among authors: kant m. Mult Scler Relat Disord. 2023 Dec;80:105127. doi: 10.1016/j.msard.2023.105127. Epub 2023 Nov 5. Mult Scler Relat Disord. 2023. PMID: 37956521
Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in Denmark.
Framke E, Sellebjerg F, Kant M, Stilund M, Jensen HB, Illes Z, Asgari N, Sejbaek T, Roug LC, Jensen MB, Schäfer J, Rasmussen PV, Christensen JR, Weglewski A, Prakash S, Magyari M; DMSG study group*. Framke E, et al. Among authors: kant m. Mult Scler. 2025 Jan;31(1):36-43. doi: 10.1177/13524585241299715. Epub 2024 Dec 4. Mult Scler. 2025. PMID: 39632560
Patterns and predictors of multiple sclerosis phenotype transition.
Pontieri L, Greene N, Wandall-Holm MF, Geertsen SS, Asgari N, Jensen HB, Illes Z, Schäfer J, Jensen RM, Sejbæk T, Weglewski A, Mahler MR, Poulsen MB, Prakash S, Stilund M, Kant M, Rasmussen PV, Svendsen KB, Sellebjerg F, Magyari M. Pontieri L, et al. Among authors: kant m. Brain Commun. 2024 Nov 23;6(6):fcae422. doi: 10.1093/braincomms/fcae422. eCollection 2024. Brain Commun. 2024. PMID: 39713244 Free PMC article.
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
Papp V, Buron MD, Siersma V, Rasmussen PV, Illes Z, Kant M, Hilt C, Mezei Z, Roshanisefat H, Sejbæk T, Weglewski A, van Wingerden J, Geertsen SS, Bramow S, Sellebjerg F, Magyari M. Papp V, et al. Among authors: kant m. PLoS One. 2021 May 18;16(5):e0250820. doi: 10.1371/journal.pone.0250820. eCollection 2021. PLoS One. 2021. PMID: 34003862 Free PMC article.
134 results